Design Therapeutics Files 8-K on Shareholder Votes

TL;DR

Design Therapeutics filed an 8-K on shareholder votes, check it for corporate actions.

AI Summary

Design Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing details the company's corporate information, including its address in Carlsbad, California, and its standard industrial classification as Pharmaceutical Preparations.

Why It Matters

This filing informs investors about important corporate actions and decisions that have been put to a vote by Design Therapeutics' shareholders.

Risk Assessment

Risk Level: low — This is a routine filing reporting on shareholder votes, not indicating new financial distress or significant operational changes.

Key Players & Entities

• Design Therapeutics, Inc. (company) — Registrant
• June 13, 2024 (date) — Date of earliest event reported
• June 17, 2024 (date) — Date of report
• Carlsbad, California (location) — Principal executive offices location

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share DSGN Nasdaq Glo

Filing Documents

• dsgn-20240613.htm (8-K) — 48KB
• 0000950170-24-074243.txt ( ) — 166KB
• dsgn-20240613.xsd (EX-101.SCH) — 26KB
• dsgn-20240613_htm.xml (XML) — 5KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 13, 2024, Design Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 18, 2024, the record date for the Annual Meeting, 56,495,039 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, where applicable, reported by rounding fractional share voting down to the nearest whole number. Proposal 1. Election of Directors The Company's stockholders elected the one person listed below as a Class III Director, to serve until the Company's 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Pratik Shah, Ph.D. 42,785,096 3,511,039 7,688,435 Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 53,981,806 2,764 2 Not applicable

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. DESIGN THERAPEUTICS, INC. Date: June 17, 2024 By: /s/ Pratik Shah, Ph.D. Pratik Shah, Ph.D. President, Chief Executive Officer and Chairperson

View Full Filing

View this 8-K filing on SEC EDGAR